zidovudine has been researched along with aplaviroc in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonny, T; Clumeck, N; Currier, J; Kleim, JP; Lazzarin, A; McCarty, D; Millard, J; Slims, J; Sloan, L; Steel, H | 1 |
| Amrine-Madsen, H; Demarest, JF; Irlbeck, DM; Kitrinos, KM | 1 |
1 review(s) available for zidovudine and aplaviroc
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for zidovudine and aplaviroc
| Article | Year |
|---|---|
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Topics: Adult; Aged; Anti-HIV Agents; Benzoates; Diketopiperazines; Double-Blind Method; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; Spiro Compounds; Treatment Outcome; Zidovudine | 2008 |
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
Topics: Anti-HIV Agents; Benzoates; Diketopiperazines; Drug Combinations; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Lamivudine; Phylogeny; Piperazines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Spiro Compounds; Treatment Failure; Tropism; Zidovudine | 2009 |
1 other study(ies) available for zidovudine and aplaviroc
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |